These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
186 related items for PubMed ID: 2663161
1. Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsiella pneumoniae. Shungu DL, Ponticas S, Gill CJ. Clin Ther; 1989; 11(3):315-8. PubMed ID: 2663161 [Abstract] [Full Text] [Related]
2. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units. Gill CJ, Ponticas S, Shungu DL, Guerriero S. Clin Ther; 1991; 13(1):25-37. PubMed ID: 2029725 [Abstract] [Full Text] [Related]
4. In vitro susceptibilities of Escherichia coli and Klebsiella spp. to ampicillin-sulbactam and amoxicillin-clavulanic acid. Kacmaz B, Sultan N. Jpn J Infect Dis; 2007 Jul; 60(4):227-9. PubMed ID: 17642541 [Abstract] [Full Text] [Related]
5. In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria. Wang FD, Lin ML, Lee WS, Liu CY. Int J Antimicrob Agents; 2004 Jun; 23(6):590-5. PubMed ID: 15194130 [Abstract] [Full Text] [Related]
6. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes. Schumacher U, Manncke B, Gerbracht K, Werner H. Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523 [Abstract] [Full Text] [Related]
7. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Cha R. Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108 [Abstract] [Full Text] [Related]
8. [Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid]. Villar HE, Jugo MB, Fernández-Lausi A, Farinati AE. Enferm Infecc Microbiol Clin; 1996 May; 14(5):308-10. PubMed ID: 8744371 [Abstract] [Full Text] [Related]
9. [Distribution and drug-resistance of 3 500 gram-negative bacteria in Guangzhou]. Xiao QZ, Su DH, Jiang JH, Zhong NS. Di Yi Jun Yi Da Xue Xue Bao; 2005 Feb; 25(2):132-8. PubMed ID: 15698988 [Abstract] [Full Text] [Related]
11. [Activity of 9 beta-lactam antibiotics combined with clavulanic acid or sulbactam against the strains of broad-spectrum beta-lactamase (CTX-1) producing Enterobacteriaceae isolated at the Henri Mondor Hospital]. Legrand P, Soussy CJ, Orsoni A, Brickley X, Duval J. Pathol Biol (Paris); 1988 May; 36(5):425-9. PubMed ID: 3043338 [Abstract] [Full Text] [Related]
17. Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Zhejiang Province. Yu Y, Zhou W, Chen Y, Ding Y, Ma Y. Chin Med J (Engl); 2002 Oct; 115(10):1479-82. PubMed ID: 12490091 [Abstract] [Full Text] [Related]
18. Differences in the evolution of imipenem susceptibility among Klebsiella pneumoniae and Escherichia coli isolates during a 6-year period in a tertiary care hospital. Papaparaskevas J, Pantazatou A, Stefanou I, Mela V, Galatidis N, Avlamis A. Int J Antimicrob Agents; 2007 Feb; 29(2):197-200. PubMed ID: 17207610 [Abstract] [Full Text] [Related]
19. Extended spectrum b lactamases (ESBL) in clinical isolates of Klebsiella pneumoniae and Escherichia coli. Duttaroy B, Mehta S. Indian J Pathol Microbiol; 2005 Jan; 48(1):45-8. PubMed ID: 16758790 [Abstract] [Full Text] [Related]
20. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina. Fernández Canigia L, Castello L, Di Martino A, Greco G, Legaria MC, Litterio M, Predari SC, Rollet R, Rossetti A, Carloni G, Sarchi MI, Bianchini H. Rev Argent Microbiol; 2007 Jan; 39(3):156-60. PubMed ID: 17987852 [Abstract] [Full Text] [Related] Page: [Next] [New Search]